Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TGFβi NK Cells for Recurrent/Refractory Brain Tumors
NCT04254419Phase 1Recruiting
- Sponsor
- Nationwide Children's Hospital
- Start
- Mar 2025
- Primary completion
- Dec 2030
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of transforming growth factor-beta-imprinted natural killer cells in high-grade glioma (HGG), sponsored by Nationwide Children's Hospital. Primary endpoint: Maximum Tolerated Dose or Recommended Phase 2 Dose at 36 months. Started Mar 2025; status: recruiting.
02
Drugs
transforming growth factor-beta-imprinted natural killer cells
03
Conditions
high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT04254419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04254419.